Borer Denton & Associates’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.69M Sell
73,287
-2,245
-3% -$106K 0.96% 23
2025
Q4
$3.84M Sell
75,532
-6,687
-8% -$342K 1.3% 20
2025
Q3
$4.56M Sell
82,219
-22,722
-22% -$1.33M 1.51% 19
2025
Q2
$7.24M Sell
104,941
-3,392
-3% -$231K 2.51% 18
2025
Q1
$7.52M Sell
108,333
-4,848
-4% -$400K 2.66% 16
2024
Q4
$9.74M Sell
113,181
-1,291
-1% -$140K 3.39% 10
2024
Q3
$13.6M Sell
114,472
-750
-0.7% -$100K 4.65% 6
2024
Q2
$16.4M Sell
115,222
-800
-0.7% -$106K 5.97% 4
2024
Q1
$14.9M Sell
116,022
-200
-0.2% -$23.8K 5.27% 4
2023
Q4
$12M Sell
116,222
-300
-0.3% -$29.7K 4.6% 6
2023
Q3
$10.6M Sell
116,522
-100
-0.1% -$8.81K 4.38% 6
2023
Q2
$9.44M Hold
116,622
3.72% 10
2023
Q1
$9.28M Buy
116,622
+6,970
+6% +$494K 3.85% 10
2022
Q4
$7.42M Hold
109,652
3.29% 14
2022
Q3
$5.46M Buy
109,652
+3,580
+3% +$192K 2.72% 17
2022
Q2
$5.91M Buy
106,072
+150
+0.1% +$8.32K 2.85% 17
2022
Q1
$5.88M Buy
+105,922
New +$5.44M 2.47% 17

Other funds holding NVO

Borer Denton & Associates's NVO Position: Q1 2026 in Review

Borer Denton & Associates reduced its Novo Nordisk (NVO) stake by 3% in Q1 2026, selling an estimated $106K and leaving 73,287 shares worth $2.69M. The position accounts for 0.96% of the portfolio, ranked #23.

Borer Denton & Associates first reported a position in NVO in Q1 2022 and has held it in 17 quarters since. The position peaked at $16.4M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Borer Denton & Associates held 73,287 shares of Novo Nordisk worth $2.69M as of Q1 2026.
  • Borer Denton & Associates sold 2,245 Novo Nordisk shares in Q1 2026, an estimated $106K.
  • Novo Nordisk made up 0.96% of Borer Denton & Associates's portfolio in Q1 2026, its #23 holding.
  • Borer Denton & Associates first reported a position in Novo Nordisk in Q1 2022 and has held it in 17 quarters since.
  • Borer Denton & Associates's Novo Nordisk position peaked at $16.4M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Borer Denton & Associates's 13F filing for Q1 2026, filed 12 May 2026.